Nuvectis Pharma (NASDAQ:NVCT – Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.01, RTT News reports. During the same quarter last year, the company posted ($0.37) earnings per share.
Nuvectis Pharma Price Performance
NVCT traded up $0.19 during trading on Thursday, reaching $8.34. 303,425 shares of the stock traded hands, compared to its average volume of 103,790. The stock has a market cap of $155.54 million, a price-to-earnings ratio of -6.47 and a beta of 0.41. The stock’s 50-day simple moving average is $6.84 and its two-hundred day simple moving average is $6.69. Nuvectis Pharma has a fifty-two week low of $5.85 and a fifty-two week high of $12.10.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reaffirmed a “buy” rating and set a $21.00 target price on shares of Nuvectis Pharma in a research note on Tuesday, August 6th.
Nuvectis Pharma Company Profile
Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.
See Also
- Five stocks we like better than Nuvectis Pharma
- The Most Important Warren Buffett Stock for Investors: His Own
- Gilead’s Stock Surge: What’s Fueling the Momentum?
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Breakout Alert: Qualcomm Just Hit The Rally Button
- What is the FTSE 100 index?
- Mercado Libre Shares Go on Sale: Is Now the Time to Buy?
Receive News & Ratings for Nuvectis Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectis Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
